Empagliflozin in Patients with Chronic Kidney Disease.
Publication Title
The New England journal of medicine
Document Type
Article
Publication Date
1-12-2023
Keywords
washington; spokane; pmrc; Humans; Diabetes Mellitus, Type 2; Creatinine; Sodium-Glucose Transporter 2 Inhibitors; Cardiovascular Diseases; Renal Insufficiency, Chronic; Kidney; Benzhydryl Compounds; Disease Progression; Glomerular Filtration Rate
Abstract
BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.
METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m
RESULTS: A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P
CONCLUSIONS: Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EudraCT number, 2017-002971-24.).
Clinical Institute
Kidney & Diabetes
Specialty
Nephrology
Specialty
Endocrinology
Recommended Citation
EMPA-KIDNEY Collaborative Group; Herrington, William G; Staplin, Natalie; Wanner, Christoph; Green, Jennifer B; Hauske, Sibylle J; Emberson, Jonathan R; Preiss, David; Judge, Parminder; Mayne, Kaitlin J; Ng, Sarah Y A; Sammons, Emily; Zhu, Doreen; Hill, Michael; Stevens, Will; Wallendszus, Karl; Brenner, Susanne; Cheung, Alfred K; Liu, Zhi-Hong; Li, Jing; Hooi, Lai Seong; Liu, Wen; Kadowaki, Takashi; Nangaku, Masaomi; Levin, Adeera; Cherney, David; Maggioni, Aldo P; Pontremoli, Roberto; Deo, Rajat; Goto, Shinya; Rossello, Xavier; Tuttle, Katherine; Steubl, Dominik; Petrini, Michaela; Massey, Dan; Eilbracht, Jens; Brueckmann, Martina; Landray, Martin J; Baigent, Colin; Haynes, Richard; and The EMPA-KIDNEY Collaborative Group, "Empagliflozin in Patients with Chronic Kidney Disease." (2023). Articles, Abstracts, and Reports. 6744.
https://digitalcommons.providence.org/publications/6744
